首页> 外文期刊>Journal of applied clinical medical physics / >Modeling and dosimetric performance evaluation of the RayStation treatment planning system
【24h】

Modeling and dosimetric performance evaluation of the RayStation treatment planning system

机译:射线处理规划系统的建模与剂量评价

获取原文
           

摘要

The physics modeling, dose calculation accuracy and plan quality assessment of the RayStation (v3.5) treatment planning system (TPS) is presented in this study, with appropriate comparisons to the more established Pinnacle (v9.2) TPS. Modeling and validation for the Elekta MLCi and Agility beam models resulted in a good match to treatment machine-measured data based on tolerances of 3% for in-field and out-of-field regions, 10% for buildup and penumbral regions, and a gamma 2%/2 mm dose/distance acceptance criteria. TPS commissioning using a wide range of appropriately selected dosimetry equipment, and following published guidelines, established the MLC modeling and dose calculation accuracy to be within standard tolerances for all tests performed. In both homogeneous and heterogeneous mediums, central axis calculations agreed with measurements within 2% for open fields and 3% for wedged fields, and within 4% off-axis. Treatment plan comparisons for identical clinical goals were made to Pinnacle for the following complex clinical cases: hypofractionated non-small cell lung carcinoma, head and neck, stereotactic spine, as well as for several standard clinical cases comprising of prostate, brain, and breast plans. DVHs, target, and critical organ doses, as well as measured point doses and gamma indices, applying both local and global (Van Dyk) normalization at 2%/2 mm and 3%/3 mm (10% lower threshold) acceptance criteria for these composite plans were assessed. In addition 3DVH was used to compare the perturbed dose distributions to the TPS 3D dose distributions. For all 32 cases, the patients QA checks showed > 95 % of pixels passing 3% global/3 mm gamma.PACS numbers: 87.55kd, 87.55km, 87.55de, 87.55dk
机译:在本研究中介绍了物理建模,剂量计算精度和计划质量评估(V3.5)治疗计划系统(TPS),具有适当的比较,更具成熟的Pinnacle(V9.2)TPS。 ELEKTA MLCI和敏捷梁模型的建模与验证导致治疗机器测量数据的良好匹配,基于现场和场外区域的公差,增加的累积和山上区域,以及一个伽玛2%/ 2 mm剂量/距离验收标准。 TPS commissioning using a wide range of appropriately selected dosimetry equipment, and following published guidelines, established the MLC modeling and dose calculation accuracy to be within standard tolerances for all tests performed.在均匀和异质介质中,中央轴计算同意,对于开放场的2%内的测量值和3%的楔形场,4%偏离轴内。治疗计划比较相同的临床目标对以下复杂的临床病例进行了巅峰:低分反向非小细胞肺癌,头部和颈部,立体定向脊柱以及若干标准临床病例,包括前列腺,脑和乳房计划。 DVHS,靶和临界器官剂量,以及测量点剂量和伽马指数,将本地和全球(VANDYK)标准化归一化为2%/ 2 mm,3%/ 3mm(10%较低的阈值)接受标准这些综合计划被评估。此外,3DVH用于将扰动剂量分布与TPS 3D剂量分布进行比较。对于所有32例,患者QA检查显示> 95%像素通过3%全球/ 3毫米Gamma.pacs编号:87.55KD,87.55km,87.55de,87.55dk

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号